Page 81 - Read Online

Tokuyasu et al. J Cancer Metastasis Treat 2018;4:2 I http://dx.doi.org/10.20517/2394-4722.2017.52 Page 19 of 24

86. Kumai T, Kobayashi H, Harabuchi Y, Celis E. Peptide vaccines in cancer—old concept revisited. Curr Opin Immunol 2017;45:1-7.
87. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol 2012;162:171-82.
88. Sayour EJ, Mitchell DA. Manipulation of innate and adaptive immunity through cancer vaccines. J Immunol Res 2017;2017:3145742.
89. Kramps T, Elbers K, editors. RNA Vaccines. New York, NY: Springer New York; 2017.
90. Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. Vaccine 2012;30:4414-8.
91. Beitelshees M, Li Y, Pfeifer BA. Enhancing vaccine effectiveness with delivery technology. Curr Opin Biotechnol 2016;42:24-9.
92. Yang Y, Hou J, Lin Z, Zhuo H, Chen D, Zhang X, Chen Y, Sun B. Attenuated listeria monocytogenes as a cancer vaccine vector for the
delivery of CD24, a biomarker for hepatic cancer stem cells. Cell Mol Immunol 2014;11:184-96.
93. Cawood R, Hills T, Wong SL, Alamoudi AA, Beadle S, Fisher KD, Fisher KD, Seymour LW. Recombinant viral vaccines for cancer.
Trends Mol Med 2012;18:564-74.
94. Swartz MA, Hirosue S, Hubbell JA. Engineering approaches to immunotherapy. Sci Transl Med 2012;4:148rv9.
95. Mehta NK, Moynihan KD, Irvine DJ. Engineering new approaches to cancer vaccines. Cancer Immunol Res 2015;3:836-43.
96. Francis DM, Thomas SN. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer
immunotherapy. Adv Drug Deliv Rev 2017;114:33-42.
97. Kirpach J, Muller CP. Epitopes. Chichester, UK: John Wiley & Sons, Ltd; 2015. p. 1-11.
98. Backert L, Kohlbacher O. Immunoinformatics and epitope prediction in the age of genomic medicine. Genome Med 2015;7:119.
99. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal
cancer. Cancer Res 2008;68:889-92.
100. Nielsen M, Lundegaard C, Lund O, Keşmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained
from improved predictions of proteasomal cleavage. Immunogenetics 2005;57:33-41.
101. Snyder A, Chan TA. Immunogenic peptide discovery in cancer genomes. Curr Opin Genet Dev 2015;30:7-16.
102. Vita R, Overton JA, Greenbaum JA, Ponomarenko J, Clark JD, Cantrell JR, Wheeler DK, Gabbard JL, Hix D, Sette A, Peters B. The
immune epitope database (IEDB) 3.0. Nucleic Acids Res 2015;43:D405-12.
103. Olsen LR, Tongchusak S, Lin H, Reinherz EL, Brusic V, Zhang GL. TANTIGEN: a comprehensive database of tumor T cell antigens.
Cancer Immunol Immunother 2017;66:731-5.
104. Lund O, Karosiene E, Lundegaard C, Larsen MV, Nielsen M. Bioinformatics identification of antigenic peptide: predicting the
specificity of major MHC class I and II pathway players. In: van Endert P, editor. Antigen processing: methods and protocols. Humana
Press, Totowa, NJ; 2013. p. 247-60.
105. Bjerregaard AM, Nielsen M, Hadrup SR, Szallasi Z, Eklund AC. MuPeXI: prediction of neo-epitopes from tumor sequencing data.
Cancer Immunol Immunother 2017;66:1123-30.
106. Schubert B, de la Garza L, Mohr C, Walzer M, Kohlbacher O. ImmunoNodes - graphical development of complex immunoinformatics
workflows. BMC Bioinformatics 2017;18:242.
107. Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu
tumor antigen. Cancer Res 2000;60:5228-36.
108. Stern LJ, Santambrogio L. The melting pot of the MHC II peptidome. Curr Opin Immunol 2016;40:70-7.
109. Hudrisier D, Gairin JE. Peptide-major histocompatibility complex class I complex: from the structural and molecular basis to
pharmacological principles and therapeutic applications. In: Whitton JL, editor. Antigen presentation.Berlin, Heidelberg: Springer;
1998. p. 75-97.
110. Faro J, Castro M, Molina-París C. A unifying mathematical framework for experimental TCR-pMHC kinetic constants. Sci Rep
2017;7:46741.
111. Yarchoan M, Johnson Iii BA, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev
Cancer 2017;17:209-22.
112. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
113. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T,
Modrusan Z, Mellman I, Lill JR, Delamarre L. Predicting immunogenic tumour mutations by combining mass spectrometry and
exome sequencing. Nature 2014;515:572-6.
114. Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS. HLA
ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic
leukemia (CLL). Proc Natl Acad Sci U S A 2015;112:E166-75.
115. Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K,
Martignoni ME, Werner A, Hein R, H Busch D, Peschel C, Rad R, Cox J, Mann M, Krackhardt AM. Direct identification of clinically
relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 2016;7:13404.
116. Bentzen AK, Marquard AM, Lyngaa R, Saini SK, Ramskov S, Donia M, Such L, Furness AJ, McGranahan N, Rosenthal R, Straten
PT, Szallasi Z, Svane IM, Swanton C, Quezada SA, Jakobsen SN, Eklund AC, Hadrup SR. Large-scale detection of antigen-specific T
cells using peptide-MHC-I multimers labeled with DNA barcodes. Nat Biotechnol 2016;34:1037-45.
117. Bunse L, Schumacher T, Sahm F, Pusch S, Oezen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D, Wiestler
B, Winkler F, Herold-Mende C, von Deimling A, Wick W, Platten M. Proximity ligation assay evaluates IDH1 R132H presentation in
gliomas. J Clin Invest 2015;125:593-606.
118. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach
K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller SB, Okun J, Stevanović S, Riemer AB, Sahin U, Friese
MA, Beckhove P, von Deimling A, Wick W, Platten M. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature